from Wedgewood Pharmacy.
Until recently, a diagnosis of Feline Infectious Peritonitis (FIP) has been a grim verdict for kittens and young adult cats, especially in shelters and multi-cat environments. But today, there's a new hope on the horizon.
Now offering both GS-441524 and Molnupiravir, Wedgewood empowers veterinarians with unmatched flexibility in treating feline infectious peritonitis. Whether as monotherapies or in combination, these options support a personalized approach to care.
Wedgewood’s pharmacists provide guidance for veterinarians to develop tailored FIP treatment protocols. Whether using GS-441524, Molnupiravir, or a combination of both, our experts ensure optimal dosing strategies for each patient. This personalized support is especially valuable in complex or refractory cases.
-Tasker, et al., "Feline Infectious Peritonitis: European Advisory Board on Cat Diseases"
Yes, GS-441524 and Molnupiravir can be used together under veterinary supervision. They offer complementary antiviral mechanisms—GS-441524 blocks viral replication, while Molnupiravir induces lethal viral mutations. This combination or personalized use of one over the other can be adjusted based on patient response. Our pharmacists are available to help develop individualized treatment protocols, even in challenging cases.
Majority of Molnupiravir and GS-441524 orders ship the same day if placed before 3 pm EST.
We use FDA-registered APIs, rigorous compounding protocols, and maintain strict quality assurance.
We ship to all 50 states, Puerto Rico, the US Virgin Islands, Canada*, Guam, and all US military bases worldwide.
*An EDR is required to ship to Canada
The oral liquids will have a 90-day BUDs from the date of compounding. The capsules will have 180 days from the day of compounding.
While resistance can develop with any antiviral, using a combination approach or switching between GS-441524 and Molnupiravir under veterinary guidance can help mitigate this risk. Our pharmacists can support personalized strategies.
*We note that Wedgewood’s formulations containing molnupiravir or GS-441524 have not been studied in any clinical trials. Wedgewood makes no claims of safety or efficacy with respect to the medications it produces and sells. The information provided herein is for informational purposes only.